2,4-Dinitrophenol, or DNP, is an industrial chemical that was proposed as an obesity drug in the early 1930s because it dramatically raises metabolic rate, then withdrawn after it caused liver failure and death
reports research support for clinical trials leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA and CSL Behring, as well as honoraria for consultancy from Lilly USA, Pfizer, Boehringer Ingelheim, Lexicon, Novo Nordisk, Applied Therapeutics, Altimmune, CSL Behring, Bayer, Intercept and New Amsterdam
Cornell Health does not auto-fill medications
Increased GI symptoms are normal during dose escalation but should be monitored alongside thyroid symptoms